Clinical Trials Browser

toripalimab × 30 days × Clear all

NCT07480733 2026-03-18

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07481058 2026-03-18

A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Phase 2 Recruiting

NSCLC

NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Phase 1/2 Terminated

Uterine Cervical Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Phase 1 Active not recruiting

Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

Carcinoma, Renal Cell

NCT06975293 2026-03-05

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Phase 1/2 Recruiting

DermatologicGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Phase 2 Recruiting

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06457503 2026-03-02

TRANSPARENT

Phase 4 Recruiting

Nasopharyngeal Neoplasms

NCT06657144 2026-03-02

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05888402 2026-02-27

InTRist

Phase 2 Active not recruiting

Local Advanced Non-small Cell Lung Cancer

NCT07281716 2026-02-19

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms